$PRGO

Perrigo (PRGO) reported weak Q2 2026 earnings with a 3.1% sales decline and 21% drop in core earnings. The company's gross and operating margins also fell. Despite paying a $0.29 dividend, risks include weak performance, asset sales, and leadership uncertainty following the abrupt departure of its CEO. Investors are advised to wait for a new CEO's plan before considering the stock.

Perrigo (PRGO) reported weaker Q2 self-care and specialty-care demand in Europe and lower store-brand minoxidil and Mederma comparisons, while U.S. OTC volumes turned positive in late July. Infant formula revenue rose 23% YoY. Core adjusted gross margin fell 250 bps to 37%. Perrigo sold Dermacosmetics for $359M, using proceeds to reduce debt, and reiterated its 2026 outlook, including about -$0.60 EPS from under-absorption.

Perrigo (Q2 2026 earnings call) said core net sales fell 3.1% due to temporary seasonal softness and European retailer destocking, while it gained market share in U.S. store-brand OTC and key European brands. The company maintained full-year 2026 guidance, expects $80m-$100m savings by 2027, and noted a $359m Dermacosmetics divestiture and reviews of Infant Formula and Oral Care.

Biotech stocks rose as several companies reported updates. Attovia Therapeutics (ATTO) jumped over 28% after its Nasdaq debut at $17 and a close at $21.90. American Well (AMWL) gained about 25% after Q2 loss narrowed to $9.6M, though revenue fell to $52.0M. Perrigo (PRGO) swung to Q2 net income of $74.5M. UroGen (URGN) rose after Q2 revenue increased to $72.5M.

Investing.com reports Perrigo (PRGO) shares rose 24.4% to $13.41 after the company posted Q2 2026 results above analyst estimates. All-in adjusted diluted EPS was $0.50 versus $0.34 expected, and revenue was about $1.02B versus $1.01B. Perrigo cited cost savings and its Three-S strategy, reaffirmed 2026 EPS guidance, and said €305.6M from the Dermacosmetics sale will aid debt reduction.

Perrigo Co. plc (PRGO) reported Q2 profit despite lower sales. Net income was $74.5M versus a $8.4M loss a year earlier. EPS was $0.53 versus a loss of $0.06. Net sales fell to $1.02B from $1.06B. Perrigo reaffirmed FY2026 outlook, with adjusted EPS of $2.00 to $2.30. Shares rose about 11% premarket to $12.

PERRIGO Co plc (PRGO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Perrigo Reports Second Quarter 2026 Financial Results From Continuing Operations • Execution of Three-S plan driving continued improvement in underlying business fundamentals, including market share growth in U.S. store-brand OTC and key European brands • Streamlined

PERRIGO Co plc (PRGO) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. prgo-20260629 0001585364 false 0001585364 2026-06-29 2026-06-29 0001585364 prgo:OrdinaryShares0001ParValueMember 2026-06-29 2026-06-29 0001585364 prgo:A4.900SeniorNoteDue2030Member 2026-06-29 2026-06-29 0001585364 prgo:A6.125SeniorNotesDue2032Member 2026-06-29 2026-06-29 00015853

PERRIGO Co plc (PRGO) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. prgo-20260630 0001585364 false 0001585364 2026-06-30 2026-06-30 0001585364 prgo:OrdinaryShares0001ParValueMember 2026-06-30 2026-06-30 0001585364 prgo:A4.900SeniorNoteDue2030Member 2026-06-30 2026-06-30 0001585364 prgo:A6.125SeniorNotesDue2032Member 2026-06-30 2026-06-30 00015853

Simply Wall St discusses governance and strategy risks for Perrigo (PRGO), noting that an extended interim period or CEO search could slow decisions on infant nutrition, cost savings and portfolio moves. It says investors may watch the CEO hire profile and any priority shifts, while Perrigo’s 2026 guidance is described as reaffirmed despite weaker demand and retailer destocking.